Ensysce Biosciences GAAP EPS of -$0.75 beats by $0.51
Seeking Alpha News (Mon, 30-Mar 4:53 PM ET)
Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results
ACCESS Newswire (Mon, 30-Mar 4:50 PM ET)
Ensysce Biosciences Targets Regulatory Risk With Strategic AMA Session as PF614 Program Gains Focus
Market Chameleon (Thu, 5-Mar 6:08 AM ET)
ACCESS Newswire (Wed, 4-Mar 8:45 AM ET)
ACCESS Newswire (Tue, 3-Mar 8:00 AM ET)
ENSC Initiates Strategic Review—Could New Partnerships Unlock Value for Shareholders?
Market Chameleon (Fri, 27-Feb 4:51 AM ET)
Follow-Through Leaders: Production Ramps, AI Alliances, Balance Sheet Strength
Globe Newswire (Fri, 27-Feb 9:45 AM ET)
Ensysce Biosciences Initiates Review of Strategic Alternatives to Enhance Shareholder Value
ACCESS Newswire (Wed, 25-Feb 8:00 AM ET)
Ensysce Biosciences Invited to Participate in Upcoming Scientific and Industry Events
ACCESS Newswire (Mon, 23-Feb 8:00 AM ET)
ACCESS Newswire (Wed, 28-Jan 8:00 AM ET)
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
Ensysce Biosciences trades on the NASDAQ stock market under the symbol ENSC.
As of April 2, 2026, ENSC stock price climbed to $0.61 with 192,550 million shares trading.
ENSC has a beta of 3.13, meaning it tends to be more sensitive to market movements. ENSC has a correlation of 0.17 to the broad based SPY ETF.
ENSC has a market cap of $2.16 million. This is considered a Sub-Micro Cap stock.
Last quarter Ensysce Biosciences reported $2 million in Revenue and -$.75 earnings per share. This beat revenue expectation by $1 million and exceeded earnings estimates by $.51.
In the last 3 years, ENSC traded as high as $108.00 and as low as $.31.
The top ETF exchange traded funds that ENSC belongs to (by Net Assets): VXF.
ENSC has underperformed the market in the last year with a price return of -75.6% while the SPY ETF gained +18.2%. ENSC has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -33.7% and -3.4%, respectively, while the SPY returned -3.6% and -0.6%, respectively.
ENSC support price is $.49 and resistance is $.60 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ENSC shares will trade within this expected range on the day.
